Regulation (EU) 2024/1860 is Regulation 32024R1860. to address risks of shortages of in vitro diagnostic medical devices in the Union and ensure the timely roll-out of Eudamed. Source: EUR-Lex and European Parliament procedure file. Methodology
Regulation (EU) 2024/1860
- CELEX
- 32024R1860
- Type
- Regulation
- Dated
- 2024-06-13
- Procedure
- 2024/0021(COD)
- Lead committee
- ENVI
- Stage
- Procedure completed
Official title: Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain in vitro diagnostic medical devices (Text with EEA relevance)
What it is
to address risks of shortages of in vitro diagnostic medical devices in the Union and ensure the timely roll-out of Eudamed. PROPOSED ACT: Regulation of the European Parliament and of the Council. ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council. BACKGROUND: Regulation (EU) 2017/745 (Medical Devices Regulation (MDR)) and Regulation (EU) 2017/746 (In Vitro Diagnostic Medical Devices Regulation (IVDR)) of the European Parliament and of the Council set a strengthened regulatory framework for medical devices and in vitro diagnostic medical devices (IVDs). The European Parliament adopted by 511 votes to 20, with 21 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, information obligation in case of interruption of supply and the transitional provisions for certain in vitro diagnostic (IVD) medical devices. The European Parliament adopted its position at first reading under the ordinary legislative procedure, taking over the Commission's proposal. The proposed regulation aims to alleviate the risk of shortages of in vitro diagnostic medical devices in the EU and to facilitate the timely deployment of Eudamed. With a view to ensuring the availability of in vitro diagnostics, the proposal aims to further extend the transitional periods to give manufacturers and notified bodies more time to complete the necessary conformity assessment procedures for certain IVDs to mitigate the risk of shortages of these products, especially of high-risk IVDs, which are used, for example, to test for infections in blood or organ donations or for blood grouping for transfusions. This extension will be subject to conditions and therefore safeguard the high level of requirements set out by the legislation and protect public health. Secondly, the proposal aims to allow a gradual roll-out of the electronic systems integrated into the European database on medical devices (Eudamed) that have already been completed, instead of waiting for the completion of the last of the six modules for the mandatory use of Eudamed. The use of Eudamed, and in particular its systems for registering economic operators, devices and certificates, should improve transparency and provide information on devices present on the EU market, thus helping to monitor device availability. Lastly, the proposal aims to impose an obligation on manufacturers to give notice before discontinuing the supply of certain critical medical devices and IVDs. This Regulation is being adopted in view of the exceptional circumstances arising from an imminent risk of shortages of in vitro diagnostic medical devices and the associated risk of a public health crisis, as well as the significant delay in the development of the electronic system on clinical investigations and performance studies of Eudamed. In order to attain the intended effect of amending Regulations (EU) 2017/745 and (EU) 2017/746 and to ensure the availability of such devices the…
Frequently asked
What is Regulation (EU) 2024/1860?
to address risks of shortages of in vitro diagnostic medical devices in the Union and ensure the timely roll-out of Eudamed. PROPOSED ACT: Regulation of the European Parliament and of the Council. ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council. BACKGROUND: Regulation (EU) 2017/745 (Medical Devices Regulation (MDR)) and Regulation (EU) 2017/746 (In Vitro Diagnostic Medical Devices Regulation (IVDR)) of the European Parliament and of the Council set a strengthened regulatory framework
When was 32024R1860 adopted?
Regulation 32024R1860 is dated 2024-06-13. The full official text is on EUR-Lex.
What is the EU legislative procedure reference?
The procedure reference is 2024/0021(COD). You can follow it on the European Parliament's procedure file.
In scope for these industries
Primary sources
Summary extracted from the European Parliament's own per-stage procedure record. Data © European Union (Decision 2011/833/EU). Methodology.
What does this mean for companies in scope?
Ask Lex - grounded, cited answers about any EU regulation, free, no signup.
Ask Lex free →Monitor this regulation
Get an email when Regulation (EU) 2024/1860 advances — free, no account. We only email on real changes.